Description

Magnapen CAS NO 56749-84-9 is a broad-spectrum, semi-synthetic penicillin antibiotic, specifically a combination of ampicillin and flucloxacillin. This synergistic formulation is engineered to combat a wide range of bacterial infections by combining the extended spectrum of ampicillin with the β-lactamase resistance of flucloxacillin. It is a critical active pharmaceutical ingredient (API) for the pharmaceutical industry, primarily used in the formulation of injectable and oral antibiotic medications to treat severe and resistant infections in hospital and clinical settings.

Application

• Pharmaceutical API: Primary use as the active ingredient in the manufacture of antibiotic formulations.
• Injectable Solutions: For parenteral administration in hospital settings to treat severe systemic infections like sepsis, pneumonia, and post-surgical infections.
• Oral Dosage Forms: Used in capsules and suspensions for treating outpatient infections such as skin and soft tissue infections, respiratory tract infections, and urinary tract infections.
• Combination Therapy: Effective against β-lactamase producing organisms, making it crucial for empiric therapy where the causative bacteria are unknown or resistant.
• Veterinary Medicine: Application in veterinary pharmaceuticals for treating bacterial infections in livestock and companion animals.
• Research & Development: Used in microbiological research and in the development of new antibiotic combination therapies and drug delivery systems.

Basic Information

Product Name	Magnapen
CAS No.	56749-84-9
Molecular Formula	C43H50Cl2N10O10S2 • xH2O
Molecular Weight	Approx. 1001.9 (Anhydrous)
Synonyms	Ampicillin/Flucloxacillin; Co-fluampicil; Flucloxacillin/Ampicillin; Flucloxacillin Sodium and Ampicillin Sodium; Magnapen; Ampicillin and Flucloxacillin Sodium; BRL 2333 + BRL 2039; (2S,5R,6R)-6-[[(2R)-2-Amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid compound with (2S,5R,6R)-6-[[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carbonyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
EINECS	Contact for details

Quality Control

Our Magnapen is manufactured under strict cGMP conditions, ensuring the highest standards of purity and consistency for pharmaceutical applications. Each batch undergoes comprehensive analytical testing, including identification, assay, impurity profiling, and microbiological examination, in compliance with major pharmacopoeial standards such as USP, EP, and BP. A detailed Certificate of Analysis (COA) is provided with every shipment, confirming compliance with agreed specifications.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). Due to its hygroscopic (moisture-sensitive) nature, the container must be kept tightly sealed in a low-humidity environment to prevent degradation. Keep away from excessive heat and incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to standard
Identification (HPLC)	Conforms to standard
Assay (HPLC)	98.0% - 102.0% (on anhydrous basis)
Water Content (KF)	≤ 5.0%
pH (10% suspension)	5.0 - 7.5
Related Substances (HPLC)	Individual impurity ≤ 1.0%; Total impurities ≤ 3.0%
Residual Solvents (GC)	Complies with ICH Q3C
Bacterial Endotoxins	< 0.25 EU/mg
Sterility (for sterile grade)	Sterile

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.